Analyst firms · Morgan Stanley · KYMR
Morgan Stanley KYMR price target and rating history
Kymera Therapeutics Inc. (KYMR) · Health Care
Morgan Stanley rates Kymera Therapeutics Inc. (KYMR) Overweight with a $70 price target, as of its latest action on Jul 3, 2025. It has published 5 rating actions on KYMR since July 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.
- Current rating
- Overweight
- Price target
- $70
- Median target, all firms
- $133
- Actions on KYMR
- 5
Morgan Stanley price target on KYMR
Every Morgan Stanley rating on KYMR
- Jul 3, 2025
- Jun 3, 2025
- Mar 2, 2022
- Aug 18, 2021
- Jul 16, 2021
How other firms rate KYMR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Outperform | $140 | Oct 9, 2026 |
| Wolfe Research | Outperform | $180 | Sep 10, 2026 |
| Deutsche Bank | Hold | $120 | Jul 30, 2026 |
| Canaccord Genuity | Buy | $106 | May 6, 2026 |
| Jefferies | Buy | Mar 16, 2026 | |
| Barclays | Overweight | $133 | Jan 28, 2026 |
Questions about Morgan Stanley and KYMR
- What is Morgan Stanley's price target for KYMR?
- Morgan Stanley's latest stated price target for Kymera Therapeutics Inc. (KYMR) is $70, from its action on Jul 3, 2025.
- What is Morgan Stanley's rating on KYMR?
- Morgan Stanley rates KYMR Overweight, a bullish rating, as of Jul 3, 2025.
- When did Morgan Stanley last change its view on KYMR?
- On Jul 3, 2025, Morgan Stanley resumes coverage at Overweight, price target $70.
- How does Morgan Stanley's KYMR target compare with other analysts?
- Across 5 firms with a KYMR price target in the last 12 months, the median target is $133.
More KYMR rating histories
All Morgan Stanley ratingsKYMR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.